Helus outlines Phase III HLP003 data and planned NDA filing
Helus said it expects top-line Phase III data for HLP003 in adjunctive MDD in Q4 2026 and targets an NDA filing in 2028, while also discussing progress in its neuropsychiatry pipeline.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.